Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2004

View Archived Issues

Vasogen highlights FY 2003 developments

CuraGen continues to advance pipeline of protein, antibody and small molecule therapeutics

Low levels of free testosterone may increase risk of Alzheimer disease

Migraine sufferers with aura and at least one attack per month at risk for cerebral infarction

CE Mark for Matritech NMP22 products

Ivax's generic glyburide/metformin hydrochloride receives approval

Pfizer discontinues development of DK-507k

GeneMax acquires license to novel assay technology

Enrollment completed in phase IIa IPL-512602 study

OraDisc A NDA accepted for filing

Phenanthrene-based glucocorticoid receptor modulators newly developed at Pfizer

Alrex safe for long-term treatment of seasonal allergic conjunctivitis

Novel cholesterol absorption inhibitors discovered at AstraZeneca

Novartis presents new modulators of Smac/IAP interaction

New tubulysin conjugates for cancer therapy claimed by Morphochem

Phase I trial of PT-523 commences enrollment

New protein kinase inhibitors for cancer therapy designed at Novartis

Novartis presents novel tyrosine kinase inhibitors with utility in leukemia

New antitumor fredericamycin derivatives discovered at Biofrontera

New program for Protherics' Angiotensin Vaccine

Novel probucol derivatives with improved PK profile presented by AtheroGenics team

Surfaxin selected for CMA Pilot 2 Program

Clinical benefits induced by roflumilast in the treatment of asthma

Promising phase III results found for indiplon in chronic insomnia

Preliminary efficacy results of a Zadaxin triple therapy in hepatitis C

Poor efficacy reported for vaccines against HIV infection

Yamanouchi and Fujisawa announce agreement to merge in 2005

NPC1L1 identified as a protein involved in intestinal cholesterol absorption and action of ezetimibe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...